The above are called immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab) that target and bind to PD-1 or PD-L1, denying PD-1 and PD-L1 linkage.
PD-1 is receptors on activated T-cells while PD-1 ligand, PD-L1, is present in normal cells (and also in some tumor cells).
Linkage of PD-1 and PD-1 ligand (PD-L1) will cause T-cells to be inactivated.
Nivolumab and pembrolizumab inhibit/ occupy PD-1 while atezolezumab inhibits/ occupies PD-L1.
Linkage of PD-L1 at tumor cells with PD-1 in immune T-cells will allow tumor cells to be invisible and evade body immune system.
Tumour cells will be ‘visible’ and dealt by our own immune system (T-cells) once the PD-1 and PD-L1 binding sites are inhibited/ occupied by PD-1 or PD-L1 inhibitors, which disable the PD-1 and PD-L1 linkage.
It’s just as simple as the above cartoon.
All patients must be happy to learn that it’s their own immune system that is fighting the cancer cells.
Immunotherapy treatment significantly improve median overall survival (OS); reducing risk of death by about 30-40%, whichever treatment you choose.
They also have better overall response rate (ORR) and lower G3-4 toxicities when compared with chemotherapy (docetaxel).
The government should improve on the snail-tortoise pace in approving new immunotherapy (and other proven) treatment so that more agents will be made available in Malaysia sooner.
Furthermore, those treatments already obtained approval by the Food and Drug Administration (FDA-USA) and European Medicines Agency (EMA-Europe).
I heard our national pharmaceutical regulatory agency (NPRA) even requests ‘additional’ testing or data i.e one year product content stability (correct me if I’m wrong), which is not a common requirement for overseas regulatory agencies. (any new breakthrough medications need to waste additional one year before can be considered for approval?!)
With more different agents, there will be more competitions amongst pharmaceutical companies and in the process will drive down price for immunotherapy treatment.
For example, atezolizumab was approved by FDA in 2016 but only obtained approval in Malaysia recently in second half of 2018.
As soon as it was approved in Malaysia, pembrolizumab (direct competitor) price fall from 20k+ per cycle (initially was 30k+ per cycle when it was launched) to 10k+ per cycle to match atezolizumab price.
So, can you see that your unnecessary delay is causing unnecessary high cost of treatment to patients who need it.
As you can see above, patients on average live around a year (in second line setting) and you already delayed approval of the treatment for 2 years. What gives?!
Cancer patients do not have so much time.